In human cancers, PI3K-AKT pathway is the most recurrently triggered pathway regulating survival, differentiation, cell growth, and cell apoptosis of tumor cells in response to a wide array of signals, and PI3K/AKT inhibitors demonstrate a more effective and also synergize with a variety of chemotherapeutics [27–30]. The gene discussed is AKT1; the disease is cancer.